Welcome to our dedicated page for VLNCF news (Ticker: VLNCF), a resource for investors and traders seeking the latest updates and insights on VLNCF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VLNCF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VLNCF's position in the market.
The Valens Company reported Q4 2021 net revenue of $18.4 million, a 12.3% decline from Q3 2021. Provincial sales surged 31.7% to $7.9 million, while adjusted gross profit margin increased to 34.1% from 27.4%. The company plans to achieve positive adjusted EBITDA by Q4 2022 and projects 2023 revenue of at least $225 million. Despite challenges from supply chain disruptions and a strategic B2B transition, management is optimistic about growth potential due to a more streamlined business model.
The Valens Company (TSX: VLNS; Nasdaq: VLNS) will release its fourth quarter and fiscal year 2021 financial results on February 28, 2022. A conference call is scheduled for March 1, 2022, at 11:00 am Eastern Time to discuss these results. Key executives will be present for a Q&A session following their remarks. The company specializes in cannabis product manufacturing for medical and recreational use, including a wide range of CBD products in the U.S. and medicinal cannabis in Australia.
The Valens Company has completed its first shipments of cannabis-infused beverages from its Greater Toronto Area facility, with initial distribution to Ontario and upcoming orders for British Columbia, Alberta, Manitoba, and Yukon. The facility, which received a micro-processing license from Health Canada in November 2021, has a capacity of over 8 million units annually. Valens plans to enhance its beverage offerings and expand B2B partnerships. A new manufacturing agreement has also been signed, demonstrating growth potential in the cannabis beverage sector.
The Valens Company will host a virtual Investor Day on February 7, 2022, at 11:00 AM ET, with registration starting at 10:45 AM ET. The event will feature discussions on 2022 corporate initiatives, financial objectives, acquisition updates, and a Q&A session. Interested investors can register here and submit questions to ir@thevalenscompany.com prior to the event. An archived webcast will be available post-event at the company's website.
The Valens Company has launched two new cannabis brands, Versus and Contraband, as part of a strategic expansion in the recreational market. The Versus brand, an evolution of the previous Verse brand, will include around 20 new SKUs and aims to position itself competitively in the value-priced segment. Meanwhile, the ultra-premium Contraband brand will introduce high-quality CNDYLND flower products. This move follows the acquisition of Verse Cannabis in September 2021, which strengthened Valens' market presence across Canada.
Green Roads, a subsidiary of The Valens Company (TSX: VLNS) (Nasdaq: VLNS), has launched its first-ever brand campaign titled "Own the Day" to promote its wellness products aimed at alleviating common health issues such as stress and sleep disorders. The campaign highlights Green Roads' commitment to helping consumers achieve personal wellness goals. Additionally, the DTC e-commerce platform has been revamped to reflect this messaging. The campaign was developed in partnership with Known, utilizing advanced AI technology for optimization.
The Valens Company (TSX: VLNS, NASDAQ: VLNS) has announced a virtual Investor Day on February 7, 2022, at 11:00 AM ET. The day will feature discussions on corporate initiatives, financial objectives, and operational insights. Despite challenges in 2021, including supply chain issues, Valens reported a significant increase in product sales and a successful transition to finished product manufacturing. The company achieved a 93% revenue share from product sales in Q3 2021 and aims for the B2C segment to reach 75-85% of revenue by 2022, following recent acquisitions.
The Valens Company (TSX: VLNS, Nasdaq: VLNS) will participate in the ATB Capital Markets 10th Annual Institutional Investor Conference on January 13, 2022. CEO Tyler Robson will join Frederico Gomes for a fireside chat titled "Model Evolution Supports Margin Expansion" at 1:20 PM ET. Investors can register for the virtual event here. Valens is a leader in cannabis manufacturing, providing high-quality products across various segments and partnering with brands globally to meet evolving consumer preferences.
The Valens Company has formed a manufacturing partnership with Montreal Cannabis Médical Inc. to provide extraction services for MTL's pre-rolls and vapes. This contract is set to commence at the end of Q1 fiscal 2022. MTL Cannabis, known for its high-quality dried flower products, has quickly become a leading brand in Canada since its October 2020 launch. Valens aims to leverage this partnership to enhance its manufacturing capabilities and market presence.
The Valens Company has entered into two strategic agreements with PMI Mexico to expand its international reach. The first agreement involves supplying CBD for PMI's clinical trials focused on anti-inflammatory applications, with shipments expected in Q1 2022. The second agreement allows Valens to manufacture and distribute Predilife products globally, enhancing its revenue potential through diversified product offerings. This partnership is expected to diversify Valens’ global strategy, providing access to several international markets.
